|
Re: No trading yet on the TSX
|
6
|
Resverlogix Corp.
|
Oct 27, 2017 11:35AM
|
|
Re: No news
|
2
|
Resverlogix Corp.
|
Sep 16, 2022 11:43AM
|
|
Re: No news
|
6
|
Resverlogix Corp.
|
Sep 17, 2022 08:12AM
|
|
Re: No news
|
5
|
Resverlogix Corp.
|
Sep 17, 2022 11:56AM
|
|
Re: No love
|
5
|
Resverlogix Corp.
|
Dec 13, 2018 12:32PM
|
|
Re: NFK meeting
|
3
|
Resverlogix Corp.
|
Feb 20, 2020 10:21AM
|
|
Re: NFK meeting
|
4
|
Resverlogix Corp.
|
Feb 19, 2020 04:26PM
|
|
Re: News report on last NR
|
8
|
Resverlogix Corp.
|
Mar 06, 2021 08:15AM
|
|
Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV
|
6
|
Zenith Epigenetics
|
Feb 22, 2022 10:24AM
|
|
Re: News from a Chinese/Japenese Article about Zenith
|
5
|
Zenith Epigenetics
|
Oct 26, 2016 07:31PM
|
|
Re: Newbie
|
4
|
Resverlogix Corp.
|
Apr 14, 2019 05:11PM
|
|
Re: New video
|
3
|
Resverlogix Corp.
|
Aug 03, 2021 11:47AM
|
|
Re: New Trial: Continuation Protocol for ZEN003694 in mCRPC Patients
|
3
|
Zenith Epigenetics
|
Oct 30, 2019 06:15PM
|
|
Re: New Share Price Contest
|
6
|
Resverlogix Corp.
|
Oct 11, 2019 12:28PM
|
|
Re: New RVX Publication in Atherosclerosis
|
5
|
Resverlogix Corp.
|
Jan 24, 2016 02:43PM
|
|
Re: New Publication
|
4
|
Resverlogix Corp.
|
Feb 28, 2023 04:29PM
|
|
Re: New Promissory Note
|
6
|
Zenith Epigenetics
|
Oct 18, 2022 09:05AM
|
|
Re: New PP on Aug 13
|
7
|
Zenith Epigenetics
|
Aug 20, 2019 10:22AM
|
|
Re: New Phase 1 NCI trial
|
6
|
Zenith Epigenetics
|
May 24, 2023 07:09PM
|
|
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
4
|
Zenith Epigenetics
|
Mar 03, 2017 10:01AM
|
